Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.

類似資料

• Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine
  著者:: Propper, D J, 等
  出版事項: (2000)
• A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma
  著者:: Middleton, M R, 等
  出版事項: (2000)
• Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a.
  著者:: Hoffmann, R., 等
  出版事項: (1998)
• Pharmacokinetics of Dacarbazine (DTIC) in Pregnancy
  著者:: Kantrowitz-Gordon, Ira, 等
  出版事項: (2018)
• Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.
  著者:: Mulder, N. H., 等
  出版事項: (1990)